VIRX - Viracta Therapeutics, Inc.

QQQ $ 439.55 $ -0.26 (-0.06 %)

DIA $ 390.50 $ 1.74 (0.45 %)

SPY $ 517.10 $ 0.05 (0.01 %)

TLT $ 90.18 $ -0.55 (-0.61 %)

GLD $ 213.58 $ -0.63 (-0.29 %)

Previous Close

$ 0.821

Open

$ 0.82

Bid

$ 0.00 x 0

Ask

$ 0.84 x 100

Day's Range

$ 0.82 - $ 0.82

52 Week Range

$ 0.43 - $ 2.38

Volume

26,818

Average Volume

Market Cap

31.71M

Beta (5Y Monthly)

$ 0.81

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-07-2024	12-31-2023	10-K
2	11-09-2023	09-30-2023	10-Q
3	08-14-2023	06-30-2023	10-Q
4	05-09-2023	03-31-2023	10-Q
5	03-14-2023	12-31-2022	10-K
6	11-10-2022	09-30-2022	10-Q
7	08-09-2022	06-30-2022	10-Q
8	05-10-2022	03-31-2022	10-Q
9	03-16-2022	12-31-2021	10-K
10	11-10-2021	09-30-2021	10-Q
11	08-12-2021	06-30-2021	10-Q
12	05-13-2021	03-31-2021	10-Q
13	02-24-2021	12-31-2020	10-K
14	11-16-2020	09-30-2020	10-Q
15	08-11-2020	06-30-2020	10-Q
16	05-07-2020	03-31-2020	10-Q
17	03-10-2020	12-31-2019	10-K
18	11-12-2019	09-30-2019	10-Q
19	08-07-2019	06-30-2019	10-Q
20	05-08-2019	03-31-2019	10-Q
21	03-07-2019	12-31-2018	10-K
22	11-05-2018	09-30-2018	10-Q
23	08-08-2018	06-30-2018	10-Q
24	05-08-2018	03-31-2018	10-Q
25	03-09-2018	12-31-2017	10-K
26	11-02-2017	09-30-2017	10-Q
27	07-27-2017	06-30-2017	10-Q
28	05-08-2017	03-31-2017	10-Q
29	03-09-2017	12-31-2016	10-K
30	11-03-2016	09-30-2016	10-Q
31	07-29-2016	06-30-2016	10-Q
32	05-09-2016	03-31-2016	10-Q
33	03-14-2016	12-31-2015	10-K
34	11-05-2015	09-30-2015	10-Q
35	07-30-2015	06-30-2015	10-Q
36	05-05-2015	03-31-2015	10-Q
37	03-12-2015	12-31-2014	10-K
38	11-10-2014	09-30-2014	10-Q
39	08-05-2014	06-30-2014	10-Q
40	05-07-2014	03-31-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
04/24/2024 12:06:37

why-travelers-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why Travelers Shares Are Trading Lower By ...
04/17/2024 17:36:19

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

12-health-care-stocks-moving-in-wednesdays-intraday-session

12 Health Care Stocks Moving In Wednesday'...
04/17/2024 16:31:40

Oppenheimer Maintains Outperform on Viract...
04/17/2024 12:49:00

Oppenheimer analyst Hartaj Singh maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $13 price target.

HC Wainwright & Co. Reiterates Buy on Vira...
04/16/2024 14:42:23

HC Wainwright & Co. analyst Robert Burns reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Buy and maintains $4 price...

why-is-small-cap-cancer-drug-developer-viracta-therapeutics-stock-trading-lower-on-monday

Why Is Small-Cap Cancer Drug Developer Vir...
04/15/2024 16:16:35

Nanatinostat combined with valganciclovir shows promising results in treating relapsed or refractory EBV+ peripheral T-cell lym...

$viracta-therapeutics-announces-topline-nana-val-results-from-stage-1-of-the-naval-1-trial-in-patients-with-relapsed-or-refractory-epstein-barr-virus-positive-peripheral-t-cell-lymphoma$

Viracta Therapeutics Announces Topline Nan...
04/15/2024 12:02:48

- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-...

Viracta Therapeutics To Present Topline Na...
04/01/2024 12:34:10

Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention o...

12-health-care-stocks-moving-in-tuesdays-intraday-session

12 Health Care Stocks Moving In Tuesday's ...
03/12/2024 17:31:12

HC Wainwright & Co. Reiterates Buy on Vira...
03/12/2024 10:20:09

HC Wainwright & Co. analyst Robert Burns reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Buy and maintains $4 price...

Why Marvell Technology Shares Are Trading ...
03/08/2024 18:47:01

Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quart...

Why Porch Group Shares Are Trading Higher ...
03/08/2024 13:23:50

Shares of Porch Group, Inc. (NASDAQ: PRCH) rose sharply in pre-market trading after the company reported better-than-expected ...

12-health-care-stocks-moving-in-fridays-pre-market-session

12 Health Care Stocks Moving In Friday's P...
03/08/2024 13:09:28

Viracta Therapeutics Completes Second-Stag...
02/29/2024 13:42:14

Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the s...

CACI International To Rally Around 21%? He...
01/05/2024 13:23:24

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

HC Wainwright & Co. Maintains Buy on Virac...
01/05/2024 11:17:47

HC Wainwright & Co. analyst Robert Burns maintains Viracta Therapeutics (NASDAQ:VIRX) with a Buy and lowers the price ta...

Viracta Therapeutics Provides Clinical Upd...
01/04/2024 13:18:55

Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by comp...

Viracta Therapeutics Says FDA Granted Orph...
12/12/2023 13:01:32

Viracta Therapeutics Announces Interim Dat...
12/04/2023 13:32:40

Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the...

RBC Capital Maintains Outperform on Viract...
11/10/2023 19:33:21

RBC Capital analyst Gregory Renza maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and lowers the price target...